ClinicalTrials.gg

Program

ercanetide

Its studies are mostly in Angelman Syndrome · Prader-Willi Syndrome, led by Neuren Pharmaceuticals.

Furthest: phase 3, since Nov 13, 20257 company-led studies, 2 open or runningNext primary completion: Oct 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Neuren Pharmaceuticals72 open or runningphase 3since Nov 13, 2025Apr 30, 2020Oct 31, 2027phase 3 · NCT07281079

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 30, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04379869 · 28 enrolled · Australia
  2. Aug 5, 20213 phase 2 studiesNCT05011851, NCT05025332, NCT05025241
  3. May 18, 2023Phase 2 study in Prader-Willi SyndromeNCT05879614 · United States
  4. Nov 13, 2025Phase 3 study in Telomeric 22q13 Monosomy SyndromeNCT07281079 · 160 planned · United States, Canada
  5. Mar 24, 2026Phase 3 study in Telomeric 22q13 Monosomy SyndromeNCT07593391 · 180 planned · United States

Ahead

  1. Oct 31, 2027Primary completion: phase 3 study in Telomeric 22q13 Monosomy SyndromeNCT07281079
  2. Oct 29, 2028Primary completion: phase 3 study in Telomeric 22q13 Monosomy SyndromeNCT07593391

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07593391Telomeric 22q13 Monosomy Syndrome · United States3RecruitingOct 29, 2028180
NCT07281079Telomeric 22q13 Monosomy Syndrome · United States, Canada3RecruitingOct 31, 2027160
NCT05879614Prader-Willi Syndrome · United States2WithdrawnJun 30, 20250
NCT05025332Pitt-Hopkins syndrome · United States2CompletedFeb 27, 202428
NCT05025241Telomeric 22q13 Monosomy Syndrome · United States2CompletedNov 1, 202318
NCT05011851Angelman Syndrome · Australia2CompletedMay 13, 202417
NCT04379869Healthy Volunteers · Australia1CompletedFeb 11, 202128

How it is read

Names in the registry

  • “NNZ-2591”, 7 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.